O’Neill Commission Report on AMR released 19 May-16
The real implications of spreading drug resistance will be felt the world over, with developing countries and large emerging nations bearing the brunt of this problem. The Review on AMR has been assessing solutions to avoid these terrible costs.
Concerned about the rising levels of drug resistance whereby microbes evolve to become immune to a known drugs, the UK Prime Minister asked economist Jim O’Neill to analyse this global problem of antimicrobial resistance (AMR) and propose concrete actions to tackle it internationally. In July 2014, the UK Government commissioned the Review on Antimicrobial Resistance in collaboration with the Wellcome Trust.
The O’Neill report ‘Tackling Drug-Resistant Infections Globally: final report and recommendations’ published 19th May 2016 first discusses the mounting problem of resistance and why action is needed to combat it and then provides an overview of the solutions that the Review thinks should be implemented to curtail unnecessary use and increase the supply of new antimicrobials. It then looks at the role of public awareness campaigns, the need to improve sanitation and hygiene, reduce pollution from agriculture and the environment, improve global surveillance, introduce rapid diagnostics and vaccines, the need to increase the number of people in this area, and use of market entry rewards and an innovation fund to generate more drugs. Finally the paper examines how these solutions can be funded and looks at ways to build political consensus around them.
More on the final report.
This Innogen contribution was used for the O’Neill Report ‘Securing New Drugs for Future Generations â€“ the Pipeline of Antibiotics’ published on 14 May 2015, which provides a high-level assessment of the development pipeline for new antibiotics, and sets out the Review’s initial proposals for the action needed at a global level to kick-start antibiotic drug discovery efforts. This includes proposals for new ways of channelling new money into early-stage research relevant to the tackling AMR; and for major global interventions to ensure that drug developers can be sure of a predictable and viable market for new antibiotics which can successfully tackle society’s most acute unmet needs.